Literature DB >> 15330257

Functions of toll-like receptors: lessons from KO mice.

Shizuo Akira1, Kiyoshi Takeda.   

Abstract

The innate immune response is a first-line defense system in which individual Toll-like receptors (TLRs) recognize distinct pathogen-associated molecular patterns (PAMPs) and exert subsequent immune responses against a variety of pathogens. TLRs are composed of an extracellular leucine-rich repeat (LRR) domain and a cytoplasmic domain that is homologous to that of the IL-IR family. Upon stimulation, TLR recruits a cytoplasmic adaptor molecule MyD88, then IL-IR-associated kinase (IRAK), and finally induces activation of NF-kappaB and MAP kinases. However, the responses to TLR ligands differ, indicating the diversity of TLR signaling pathways. Besides MyD88, several novel adaptor molecules have recently been identified. Differential utilization of these adaptor molecules may provide the specificity in the TLR signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15330257     DOI: 10.1016/j.crvi.2004.04.002

Source DB:  PubMed          Journal:  C R Biol        ISSN: 1631-0691            Impact factor:   1.583


  58 in total

1.  Human metapneumovirus glycoprotein G inhibits TLR4-dependent signaling in monocyte-derived dendritic cells.

Authors:  Deepthi Kolli; Xiaoyong Bao; Tianshuang Liu; Chao Hong; Tian Wang; Roberto P Garofalo; Antonella Casola
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

2.  TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts.

Authors:  Thomas B Thornley; Michael A Brehm; Thomas G Markees; Leonard D Shultz; John P Mordes; Raymond M Welsh; Aldo A Rossini; Dale L Greiner
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

3.  Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant.

Authors:  Meini Wu; Haixuan Wang; Jiandong Shi; Jing Sun; Zhiqing Duan; Yanhan Li; Jianfang Li; Ningzhu Hu; Yiju Wei; Yang Chen; Yunzhang Hu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

5.  Regional elevations in microglial activation and cerebral glucose utilization in frontal white matter tracts of rhesus monkeys following prolonged cocaine self-administration.

Authors:  Hilary R Smith; Thomas J R Beveridge; Susan H Nader; Michael A Nader; Linda J Porrino
Journal:  Brain Struct Funct       Date:  2019-02-12       Impact factor: 3.270

6.  Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.

Authors:  David N Nguyen; Kerry P Mahon; Ghania Chikh; Phillip Kim; Hattie Chung; Alain P Vicari; Kevin T Love; Michael Goldberg; Steve Chen; Arthur M Krieg; Jianzhu Chen; Robert Langer; Daniel G Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-15       Impact factor: 11.205

Review 7.  Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?

Authors:  Alex Boye; Yu-Hong Zou; Yan Yang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 8.  Emerging role of Toll-like receptors in atherosclerosis.

Authors:  Linda K Curtiss; Peter S Tobias
Journal:  J Lipid Res       Date:  2008-11-01       Impact factor: 5.922

9.  Tumor suppressor Foxo3a is involved in the regulation of lipopolysaccharide-induced interleukin-8 in intestinal HT-29 cells.

Authors:  Lobke Snoeks; Christopher R Weber; Jerrold R Turner; Mitra Bhattacharyya; Kaarin Wasland; Suzana D Savkovic
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

Review 10.  Induction of type I interferon by RNA viruses: cellular receptors and their substrates.

Authors:  Alina Baum; Adolfo García-Sastre
Journal:  Amino Acids       Date:  2009-11-01       Impact factor: 3.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.